Want to see JP:2934 full AI Analyst Report?
J Frontier Co., Ltd. (2934) AI Stock Analysis
J Frontier Co., Ltd.
(TSE/TYO:2934)
The score is held down primarily by weak financial performance quality—high leverage alongside inconsistent profitability (net loss in 2026) despite improving revenue and positive free cash flow. Technicals add a modest headwind as price is below key short-term averages with slightly negative momentum. Valuation provides limited support due to a negative P/E and no stated dividend yield.
J Frontier Co., Ltd. (2934) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 10.41B
- Dividend Yield
- ―
- Average Volume (3M)
- 7,434
- Price to Earnings (P/E)
- -34.7
- Beta (1Y)
- 0.04
- Revenue Growth
- 9.77%
- EPS Growth
- -470.54%
- Country
- Japan
- Employees
- 201
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
J Frontier Co., Ltd. Business Overview & Revenue Model
Company Description
J Frontier Co.,Ltd. engages in the healthcare sales, medical care sales, and healthcare marketing businesses in Japan. The company operates SOKUYAKU, a platform for online medical treatment, online medication guidance, home delivery of prescription d...
How the Company Makes Money
Detailed, source-backed information on J Frontier Co., Ltd.’s revenue model (e.g., primary revenue streams, segment mix, pricing/fee structure, and material partnerships) was not available in the provided context. null
J Frontier Co., Ltd. Financial Statement Overview
Summary
Financials show a fragile recovery: revenue growth re-accelerated to 3.2% in 2026 and cash flow has been positive in 2025–2026, but profitability is volatile with a return to net loss in 2026. Balance sheet risk is a key drag as debt increased (~¥5.3B) while equity declined (~¥1.23B), leaving high leverage and reduced flexibility.
Income Statement
44NeutralBalance Sheet
33NegativeCash Flow
52Neutral| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.08B | 22.24B | 21.50B | 17.71B | 11.88B | 16.84B |
| Gross Profit | 8.77B | 8.36B | 18.17B | 8.33B | 5.40B | 7.12B |
| EBITDA | 1.01B | 963.76M | 914.54M | -1.22B | 760.66M | -1.54B |
| Net Income | 69.27M | -321.31M | 87.57M | -2.09B | 400.52M | -1.90B |
Balance Sheet | ||||||
| Total Assets | 8.83B | 9.59B | 9.17B | 11.41B | 6.10B | 7.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.89B | 2.16B | 2.17B | 1.81B | 2.96B | 1.65B |
| Total Debt | 4.04B | 5.31B | 4.34B | 5.16B | 544.39M | 2.14B |
| Total Liabilities | 6.83B | 8.05B | 7.16B | 9.53B | 1.94B | 4.54B |
| Stockholders Equity | 1.37B | 1.23B | 1.41B | 1.14B | 4.14B | 2.48B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 395.24M | 447.19M | -1.54B | -377.40M | -1.94B |
| Operating Cash Flow | 0 | 454.32M | 509.01M | -1.44B | -366.94M | -1.83B |
| Investing Cash Flow | 0 | -1.13B | 470.79M | -1.79B | -860.09M | -1.13B |
| Financing Cash Flow | 0 | 693.89M | -623.13M | 3.39B | 2.56B | 1.45B |
J Frontier Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2934, the sentiment is Negative. The current price of 1908.00 is below the 20-day moving average (MA) of 1973.60, below the 50-day MA of 1994.98, and above the 200-day MA of 1648.06, indicating a neutral trend. The MACD of -10.82 indicates Positive momentum. The RSI at 45.22 is Neutral, neither overbought nor oversold. The STOCH value of 61.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2934.
J Frontier Co., Ltd. Peers Comparison
Overall Rating
JP:448372Outperform
JP:921867.8Neutral
JP:448063Neutral
JP:443850Neutral- JP:293444.2Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4483 | 72Outperform | JPY 241.50B | 34.84 | ― | 0.49% | 18.89% | 11.66% |
| JP:9218 | 68Neutral | JPY 8.05B | 33.86 | ― | 1.31% | 27.65% | -28.38% |
| JP:4480 | 63Neutral | JPY 75.89B | 39.69 | 12.35% | ― | 24.03% | 34.50% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4438 | 50Neutral | JPY 2.36B | -4.42 | ― | ― | 14.84% | 30.67% |
| JP:2934 | 44Neutral | JPY 10.41B | -34.65 | ― | ― | 9.77% | -470.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2934 | J Frontier Co., Ltd. | 1950.00 | 133.00 | 7.32% | |
| JP:4480 | Medley, Inc. | 2386.00 | 280.00 | 13.30% | |
| JP:4438 | Welby Inc. | 276.00 | -13.00 | -4.50% | |
| JP:4483 | JMDC Inc. | 3690.00 | -1186.28 | -24.33% | |
| JP:9218 | Mental Health Technologies Co. Ltd. | 766.00 | -69.34 | -8.30% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026